BRIEF-Celldex Announces Barzolvolimab Met All Primary And Secondary Endpoints With High Statistical Significance In Positive Phase 2 Study In Chronic Inducible Urticaria

Reuters10-28

Oct 28 (Reuters) - Celldex Therapeutics Inc :

* CELLDEX ANNOUNCES BARZOLVOLIMAB MET ALL PRIMARY AND SECONDARY ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE IN POSITIVE PHASE 2 STUDY IN CHRONIC INDUCIBLE URTICARIA

((Reuters.Briefs@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478122949?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-28 15:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478122949","market":"us","top_or_hot":-1,"title":"BRIEF-Celldex Announces Barzolvolimab Met All Primary And Secondary Endpoints With High Statistical Significance In Positive Phase 2 Study In Chronic Inducible Urticaria","media":"Reuters","content":"<html><body><p>Oct 28 (Reuters) - Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * CELLDEX ANNOUNCES BARZOLVOLIMAB MET ALL PRIMARY AND SECONDARY ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE IN POSITIVE PHASE 2 STUDY IN CHRONIC INDUCIBLE URTICARIA</p><p>((Reuters.Briefs@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Celldex Announces Barzolvolimab Met All Primary And Secondary Endpoints With High Statistical Significance In Positive Phase 2 Study In Chronic Inducible Urticaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Celldex Announces Barzolvolimab Met All Primary And Secondary Endpoints With High Statistical Significance In Positive Phase 2 Study In Chronic Inducible Urticaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-28 15:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 28 (Reuters) - Celldex Therapeutics Inc   :   * CELLDEX ANNOUNCES BARZOLVOLIMAB MET ALL PRIMARY AND SECONDARY ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE IN POSITIVE PHASE 2 STUDY IN CHRONIC ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2478122949","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478122949","pubTimestamp":1730101323,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 28 (Reuters) - Celldex Therapeutics Inc   :   * CELLDEX ANNOUNCES BARZOLVOLIMAB MET ALL PRIMARY AND SECONDARY ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE IN POSITIVE PHASE 2 STUDY IN CHRONIC INDUCIBLE URTICARIA((Reuters.Briefs@thomsonreuters.com))","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLDX":"塞德斯医疗"},"translate_title":"BRIEF-Celldex宣布Barzolvolimab在慢性诱导性荨麻疹2期阳性研究中达到了所有主要和次要终点，具有高度统计学意义","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDX":0.9},"content_text":"Oct 28 (Reuters) - Celldex Therapeutics Inc   :   * CELLDEX ANNOUNCES BARZOLVOLIMAB MET ALL PRIMARY AND SECONDARY ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE IN POSITIVE PHASE 2 STUDY IN CHRONIC INDUCIBLE URTICARIA((Reuters.Briefs@thomsonreuters.com))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478122949"}